Broker Recommendations

Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK

By Iain Gilbert

Date: Tuesday 27 Jan 2026

(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
Citi started AstraZeneca with a 'buy' rating and a 170p target price, arguing that the drugmaker was set to deliver the fastest...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page